ETHYL 4-(13-CHLORO-4-AZATRICYCLO[9.4.0.0(3,8)]PENTADECA-1(11),3(8),4,6,12,14-HEXAEN-2-YLIDENE)PIPERIDINE-1-CARBOXYLATE

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

FDA’s list of off-patent drugs suggests higher approvals of first generics in 2022

We usher in 2023 with the key highlights of the US Food and Drug Administration’s December 202